RecruitingNCT05363319

An Observational Study to Assess the Effectiveness and Safety of a Cemiplimab in Adult Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) in Routine Clinical Practice Settings in Europe

An Observational Study to Assess the Effectiveness and Safety of Cemiplimab Based Regimen in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) in Routine Clinical Practice Settings in Europe (CEMI-LUNG)

Sponsor

Regeneron Pharmaceuticals

Enrollment

500 participants

Start Date

Oct 26, 2022

Study Type

OBSERVATIONAL

Conditions

Non-small Cell Lung Cancer

Summary

This study is focused on patients with non-small cell lung cancer (NSCLC) and have been prescribed a cemiplimab (Libtayo®) based treatment regimen under standard care. The goal of this study is to learn more about the use, benefits, and safety of cemiplimab based treatment regimens in participants with NSCLC.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This observational study across Europe is tracking how well cemiplimab — an immunotherapy drug — works and how safe it is in everyday clinical practice for adults with advanced non-small cell lung cancer (NSCLC), outside of a controlled trial setting. **You may be eligible if...** - You are 18 or older - You have been diagnosed with advanced squamous or non-squamous NSCLC confirmed by biopsy - Your doctor has prescribed cemiplimab as part of your regular care (per standard guidelines) - You are able to complete study questionnaires - You can provide written informed consent **You may NOT be eligible if...** - You are receiving cemiplimab in a different clinical trial - You are unable to complete questionnaires or provide consent - You do not meet the prescribing guidelines for cemiplimab in your country Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGCemiplimab

solution for injection via intravenous (IV) infusion

DRUGPlatinum-based chemotherapy

IV administration

Locations(49)

Klinikum Klagenfurt

Klagenfurt, Carinthia, Austria

Salzburger Landeskliniken (SALK)

Salzburg, Austria

Le Groupe Hospitalier de la Region de Mulhouse et Sud Alsace, Emile Muller Hospital

Mulhouse, Alsace, France

APHM - Hopital Nord

Marseille, Bouches-du-Rhône, France

Centre Hospitalier Universitaire (CHU) de Poitiers

Poitiers, New Aquitaine, France

Sainte Catherine Institut du Cancer Avignon Provence

Avignon, Vaucluse, France

Centre Hospitalier Universitaire Angers

Angers, France

Center Hospitalier Universitaire (CHU) of Clermont

Clermont-Ferrand, France

Centre Hospitalier - Le mans

Le Mans, France

Hopital Tenon

Paris, France

Hopitaux Universitaires de Strasbourg

Strasbourg, France

Klinikum Konstanz

Konstanz, Baden-Wurttemberg, Germany

MedFISMO

Weinsberg, Baden-Wurttemberg, Germany

Staedtisches Klinikum Muenchen Bogenhausen

München, Bavaria, Germany

Franziskus Hospital Harderberg

Georgsmarienhütte, Georgsmarienhuette, Germany

Agaplesion Diakonieklinikum Rotenburg

Rotenburg (Wümme), Lower Saxony, Germany

St. Franziskus Hospital Münster

Münster, North Rhine-Westphalia, Germany

Haematologisch Onkologische Schwerpunktpraxis - Troisdorf

Troisdorf, North Rhine-Westphalia, Germany

Klinikum Chemnitz gGmbH

Chemnitz, Saxony, Germany

Pneumologische Praxis PD Dr. Med Christian Gessner

Leipzig, Saxony, Germany

Gemeinschaftskrankenhaus Havelhoehe

Berlin, Germany

Gesellschaft fur Onkologische Studien Dortmund mbH (Gefos)

Dortmund, Germany

Krankenhaus Martha-Maria Halle-Doelau gGmbH

Halle, Germany

Marienhaus Klinikum Mainz

Mainz, Germany

Nuremberg Hospital, Campus North

Nuremberg, Germany

Humanitas Istituto Clinico Catanese

Misterbianco, Catania, Italy

AOU Careggi

Florence, Firenze, Italy

IRCCS Humanitas Research Hospital

Rozzano, Milan, Italy

San Luigi Gonzaga University Hospital

Orbassano, Piedmont, Italy

Ospedale Di Cisanello Azienda Ospedaliero Universitaria

Pisa, Tuscany, Italy

AO Universitaria Policlinico Vittorio Emanuele

Catania, Italy

Fondazione IRCCS Istituto Nazionale dei Tumori

Milan, Italy

Azienda Ospedaliero-Universitaria di Modena

Modena, Italy

AORN dei Colli

Naples, Italy

Istituto Nazionale Tumori IRCCS Fondazione G Pascale

Naples, Italy

Fondazione IRCCS Policlinico San Matteo

Pavia, Italy

Azienda Sanitaria Locale (ASL) Taranto

Taranto, Italy

Azienda Sanitaria Universitaria Friuli Centrale (ASU FC) Santa Maria della Misericordia

Udine, Italy

Hospital Universitario Virgen De La Victoria Malaga

Málaga, Andalusia, Spain

Parc Tauli Sabadell Hospital Universitari

Sabadell, Barcelona, Spain

Hospital Universitario De Jerez

Jerez de la Frontera, Cadiz, Spain

Consorcio Hospitalario Provincial de Castellon

Castellon, Castellon, Spain

Complejo Hospitalario Universitario de Ferrol - Hospital Naval

Ferrol, Galicia, Spain

Hospital Universitario Alvaro Cunqueiro

Vigo, Galicia, Spain

Hospital Torrecardenas

Almería, Spain

University Hospital of Jaen

Jaén, Spain

Hospital Arnau de Vilanova

Lleida, Spain

Hospital Universitario Nuestra Senora de Candelaria

Santa Cruz de Tenerife, Spain

Hospital Universitari Sant Joan de Reus

Tarragona, Spain

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05363319

Related Trials

A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)

NCT06692738301 locations

Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors

NCT0621891418 locations

OSIREAL - Osimertinib RWE on EGFRm NSCLC in Spain

NCT0606804925 locations

A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%

NCT06561386299 locations

A Phase 1, Dose-escalation Study of [225Ac]-FPI-2068 in Adult Patients With Advanced Solid Tumours

NCT0614703715 locations